tbuckley/cabot-search huggingface dataset:
CNS delivery of targeted protein degraders
Authors: Prashant Agarwal, Darren L. Reid, Mansoor Amiji
Journal: Journal of Controlled Release (2024)

Heterobifunctional small molecule degraders are a subset of targeted protein degraders (TPDs), consisting of two ligands joined by a linker to induce proteasomal degradation of a target protein. As compared to traditional small molecules these compounds generally demonstrate inflated physicochemical properties, which may require innovative formulation strategies to enable their delivery and exert pharmacodynamic effect. The blood brain barrier (BBB) serves an essential function in human physiology, but its presence requires advanced approaches for treating central nervous system (CNS) diseases. By integrating emerging modalities like TPDs with conventional concepts of drug delivery, novel strategies to overcome the BBB can be developed. Amongst the available routes, lipid and polymer-based long-acting delivery seems to be the most amenable to TPDs, due to their ability to encapsulate lipophilic cargo and potential to be functionalized for targeted delivery. Another key consideration will be understanding E3 ligase expression in the different regions of the brain. Discovery of new brain or CNS disease specific E3 ligases could help overcome some of the barriers currently associated with CNS delivery of TPDs. This review discusses the current strategies that exist to overcome and improve therapeutic delivery of TPDs to the CNS.
A loss-of-function variant in <i>KLF4</i> affecting zinc finger motifs causes progressive symmetric erythrokeratodermia
Authors: Zijuan Wang, Zeqiao Zhang, Jun Liu, Huijun Wang, Zhimiao Lin
Journal: British Journal of Dermatology (2024)

We identified a novel de novo variant (c.1234C &amp;gt; A, p.His412Asn) in KLF4, which is located within the first zinc finger motifs of KLF4, in a patient with progressive symmetric erythrokeratodermia. By dual-luciferase reporter assay, quantitative reverse transcriptase-polymerase chain reaction and immunofluorescence, we demonstrated that the KLF4 variant is a loss-of-function mutation, and the expression of SLURP1 and DSG1, both of which are transcriptionally regulated by KLF4, was downregulated.
Racial discrimination and health-care system trust among American adults with and without cancer
Authors: Jordyn A Brown, Brianna D Taffe, Jennifer A Richmond, Mya L Roberson
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Background Racial and ethnic minoritized groups report disproportionately lower trust in the health-care system. Lower health-care system trust is potentially related to increased exposure to racial discrimination in medical settings, but this association is not fully understood. We examined the association between racial discrimination in medical care and trust in the health-care system among people with and without a personal cancer history. Methods We examined racial discrimination and trust in a nationally representative American adult sample from the Health Information National Trends Survey 6. Racial discrimination was defined as any unfair treatment in health care on the basis of race or ethnicity. Trust in the health-care system (eg, hospitals and pharmacies) was grouped into low, moderate, and high trust. Multinomial logistic regression models were used to compare low and moderate trust relative to high trust in the health-care system and estimate odds ratios (ORs) and 95% confidence intervals (CIs). Results A total of 5813 respondents (15% with a personal cancer history) were included; 92% (n = 5355) reported no prior racial discrimination experience during medical treatment. Prior experiences of racial discrimination were positively associated with low (OR = 6.12, 95% CI = 4.22 to 8.86) and moderate (OR = 2.70, 95% CI = 1.96 to 3.72) trust in the health-care system relative to high trust. Similar associations were observed when stratifying by personal cancer history. Conclusion Respondents who reported racial discrimination during medical encounters had lower trust in the health-care system, especially respondents with a personal cancer history. Our findings highlight the need to address racial discrimination experiences during medical care to build patient trust and promote health-care access.
Genome-Wide Polygenic Risk Score Predicts Incident Type 2 Diabetes in Women With History of Gestational Diabetes
Authors: Jaewon Choi, Hyunsuk Lee, Alan Kuang, Alicia Huerta-Chagoya, Denise M. Scholtens, Daeho Choi, Minseok Han, William L. Lowe, Alisa K. Manning, Hak Chul Jang, Kyong Soo Park, Soo Heon Kwak
Journal: Diabetes Care (2024)

Women with a history of gestational diabetes mellitus (GDM) are at increased risk of developing type 2 diabetes (T2D). It remains unclear whether genetic information improves prediction of incident T2D in these women.
182P A real-world, multicenter study of atezolizumab plus bevacizumab in viral and non-viral advanced hepatocellular carcinoma patients from Asia and Europe
Authors: F. Rossari, T. Tada, S. Shimose, M. Kudo, C. Yoo, J. Cheon, F. Finkelmeier, H.Y. Lim, J. Presa, G. Masi, F. Bergamo, E. Amadeo, F. Vitiello, S. Foti, S. Camera, M. Persano, B. Stefanini, M. Scartozzi, M. Rimini, A. Casadei Gardini
Journal: Annals of Oncology (2024)
212P A phase II study of cabozantinib and temozolomide in advanced progressive gastroenteropancreatic or lung neuroendocrine tumors (NETs)
Authors: O. Clemente, M. Cives, L.P. Guerrera, M.L. Tornesello, A. Bracigliano, E. Lauricella, A. Ragno, G. Della Vittoria Scarpati, N. Starita, F. Picozzi, M.L. Barretta, G. Badalamenti, L. Cannella, S. Lastoria, A. Di Mauro, C.G. Porta, S. Tafuto
Journal: Annals of Oncology (2024)
178P Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: An updated meta-analysis and meta-regression of observational studies
Authors: M.S. Abdelgalil, B. Ehab Amer, N. Yasen, M. El-Samahy, A.K. Awad, B. Elfakharany, O. Saeed, M. Abd-Elgawad
Journal: Annals of Oncology (2024)
201P Retrospective multicenter real-life study evaluating the efficacy of atezolizumab in combination with bevacizumab in metastatic hepatocellular carcinoma: HIREAL study
Authors: F. Moinard-Butot, J-B. Barbe-Richaud, S. Husson Wetzel, M. Bolliet, P. Chiappa, C. Belletier, M. Ribeiro, E. Poprawa, C. Bigot, A. Abergel, M. Ben Abdelghani
Journal: Annals of Oncology (2024)
184P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)
Authors: M. Persano, M. Rimini, S. Foti, S. Camera, F. Rossari, E. Amadeo, F. Vitiello, T. Tada, G. Suda, S. Shimose, M. Kudo, C. Yoo, J. Cheon, F. Finkelmeier, H.Y. Lim, J. Presa, L. Mascia, S. Cascinu, M. Scartozzi, A. Casadei Gardini
Journal: Annals of Oncology (2024)
195P Risk factors in patients with hepatocellular carcinoma: A German claims data analysis
Authors: S. Becht, K. Berger-Thürmel, M. von Bergwelt, P. Buggisch, W-P. Hofmann, U. Marschall, J. Mayerle, S. Orabi, A.B. Philipp, S. Schrodi, J. Trojan, E.N. De Toni, N. Ben Khaled
Journal: Annals of Oncology (2024)
188P Early mortality in atezolizumab/bevacizumab for unresectable hepatocellular carcinoma: European, real-world study
Authors: N. Ben Khaled, L. Jochheim, K. Boettcher, B. Scheiner, F. Sinner, S.J. Gairing, M. Alunni-Fabbroni, M. Thaler, O. Oecal, D. Anz, J. Ricke, U. Ehmer, M. Venerito, F. Foerster, M. Pinter, J. Mayerle, A. Geier, E.N. De Toni, F.P. Reiter, I. Piseddu
Journal: Annals of Oncology (2024)
189P The synergic effect of metformin and atezolizumab/bevacizumab in diabetic HCC patients: A retrospective study from ARTE multicentric Italian dataset
Authors: A. Dalbeni, A. Auriemma, B. Stefanini, C. Vivaldi, P. Federico, A. Palloni, C. Soldà, I. Garajova, S. Tamberi, S. De Lorenzo, F. Piscaglia, G. Masi, S. Leonardi, G. Brandi, B. Daniele, F. Trevisani, F. Marra, F. Tovoli, M. Milella, D. Sacerdoti
Journal: Annals of Oncology (2024)
180P A systematic review with meta-analysis of risks and benefits of tyrosine kinase inhibitors in hepatocellular carcinoma treatment
Authors: J. Martínez-Geijo, T. Payo-Serafín, C. Méndez-Blanco, P. Fernández Palanca, A. García Palomo-Pérez, J.J. Ortiz de Urbina González, B. San-Miguel, M.J. Tuñón, J.L. Mauriz
Journal: Annals of Oncology (2024)
207P Diagnostic value of 18F-FDG PET-CT and MTV as a prognostic factor in patients with multifocal hepatocellular carcinoma T2-3N0M0, BCLC-B in the «downstaging» or «bridge» mode treatment to liver transplantation and liver transplantation planning
Authors: Y. Yermakovich-Sauchuk, A. Bialiutsin, A. Shcherba, D. Liovina
Journal: Annals of Oncology (2024)
186P Patients’ characteristics, outcomes, and costs of liver transplantation in patients with hepatocellular carcinoma in Germany
Authors: S. Schrodi, S. Becht, M. von Bergwelt, P. Buggisch, W-P. Hofmann, U. Marschall, J. Mayerle, A.B. Philipp, J. Trojan, E.N. De Toni, N. Ben Khaled, K. Berger-Thürmel
Journal: Annals of Oncology (2024)
209P Setup of hepatocellular carcinoma (HCC) multidisciplinary teams (MDTs) demonstrate multi-faceted similarities and differences across US, Canada and Europe
Authors: P.S. Azcue, M. Kothari, C. Schnatwinkel, W. Vereecken, S. Rohr, J. Vega, M. Gallego-Llorente, Y.P. Cui, M.T. Campos Partera, A. Moucquot, H. Naqvi, D. Dellamonica
Journal: Annals of Oncology (2024)
183P Lenvatinib versus sorafenib for recurrence of hepatocellular carcinoma after liver transplantation
Authors: S. Perera, C.T.J. Magyar, L. Rajendran, Z. Li, F.A. Almugbel, S. Feng, W.J. Choi, L. Aceituno, N. Selzner, E. Jaeckel, N. Falla-Rad, J.J. Knox, E.X. Chen, G.M. O'Kane, G. Sapisochin
Journal: Annals of Oncology (2024)
154P Investigating the potential of estrogen-related receptor gamma (ERRγ) in colorectal cancer and examining the therapeutic implications of DN200434 (ERRγ inverse agonist) &amp; MK2206 (Akt inhibitor)
Authors: D. Gulwani, P. Upadhyay, R. Goel, P. Das, T. Singh
Journal: Annals of Oncology (2024)
145P Incorporating ctDNA-based MRD test into clinical practice for CRC: Prospective Japanese real-world data
Authors: Y. Fukumoto, K. Kataoka, K. Ito, K. Kimura, N. Beppu, J. Song, A. Imada, M. Otani, T. Matsubara, Y. Horio, R. Kuwahara, M. Uchino, H. Ikeuchi, E. Oki, M. Ikeda
Journal: Annals of Oncology (2024)
153P Determinants of tumour-immune evolutionary trajectory in colorectal cancer
Authors: E. Lakatos, V. Gunasri, L. Zapata, J. Househam, T. Heide, N. Trahearn, O. Swinyard, C. Lynn, G. Cresswell, M. Mossner, C. Kimberley, I. Spiteri, M. Jansen, M. Rodriguez-Justo, J.A. Bridgewater, A-M. Baker, A. Sottoriva, T. Graham
Journal: Annals of Oncology (2024)
Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models
Authors: Lindsay Kua, Chee Hoe Ng, Jin Wei Tan, Hwee Ching Tan, Cheah Chen Seh, Fiona Wong, Richard Ong, Cliona M. Rooney, Joel Tan, Qingfeng Chen, Ivan D. Horak, Kar Wai Tan, Lionel Low
Journal: Molecular Therapy (2024)
142P Angiotensin receptor blockers and severe diarrhea and/or enterocolitis induced by CAPOX in patients with colorectal cancer: A multicentric cohort
Authors: A.F. Teixeira, T.C. Felismino, M.D. Spina Donadio, G. Catani, A.L. Mattos, R. Weschenfelder, J.M.R. O'Connor, R.D. Peixoto, A. Kruschewsky Coutinho Araujo, R.S.P. Riechelmann
Journal: Annals of Oncology (2024)
165MO Early detection of HCC by routine blood based-AI
Authors: K.N. Kwok, K.M. Cheung, S.J.L. Lam, H. Lam, W. Sung, H. Liu, P.Y.M. Woo, A.S.M. Yip, K.K.H. Bao, J.C-H. Chow, O.P. Chiu, S. Lam, M. Lee, G.T.C. Cheung, S.K.K. Ng, D.M.Y. Kan, H.H.Y. Yiu, D.C.C. Lam
Journal: Annals of Oncology (2024)
170P Efficacy of the combination of transarterial chemoembolization (TACE) and immunotherapy of atezolizumab + bevacizumab in patients before liver resection and transplantation (OTP) with hepatocellular carcinoma (HCC)
Authors: K.A. Nasonova, A.A. Zagidullina, V.V. Breder, M. Khagazheeva, N. Kudashkin
Journal: Annals of Oncology (2024)
160TiP A phase I/II study of CFT1946, a novel BIDAC degrader targeting mutant BRAF V600 solid tumors including metastatic colorectal cancer (CRC) in combination with cetuximab
Authors: M. Vieito Villar, M. McKean, A. Spira, E. Rosen, J. Rodon, V. Moreno, V. Gambardella, O. Saavedra Santa Gadea, S. Cousin, P. Cassier, I. Korakis, B.A. Van Tine, J.S. Wang, V.T-L. Ma, M.E. Elez Fernandez, M. Pelster, E. Hinojosa, R. Lobbardi, E. Hurh, E. Buchbinder
Journal: Annals of Oncology (2024)
159TiP COPERNIC: A study of on-treatment circulating tumour (ct)DNA changes in chemo-refractory colorectal cancer (CRC) patients
Authors: I. Assaf, G. Bregni, G. Anthoine, T. Aparicio, P. Artru, M. Ben Abdelghani, B. Chibaudel, E. Coart, M. Diaz, C. Evrard, K. Geboes, F. Ghiringhelli, F. Puleo, J. Raimbourg, T. Vandamme, M. van den Eynde, A. Hendlisz, F. Sclafani
Journal: Annals of Oncology (2024)
168P Characterization of tumor response with lenvatinib (LEN) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT
Authors: A. Mahipal, A-L. Cheng, M. Kudo, A. Burgoyne, A. Kalyan, R. Lencioni, C. Lopez, M. Pracht, B. Daniele, D. Palmer, A. Baron, J-W. Park, K. Estenson, V. Christou, M. Ren, A. Vogel
Journal: Annals of Oncology (2024)
124P Acquired resistance to first-line chemo- and EGFRab-therapy in mCRC: Biopsy analysis of the iSCORE trial
Authors: R. Lane, J. Mencel, F. Turkes, B.R. Challoner, N. McCafferty, P. Ntellas, L.J. Barber, I. Rana, H-C. Chen, R. Begum, M. Ficial, A. Tran, M. Terlizzo, S. Rao, D. Cunningham, I. Chau, N. Starling, M. Gerlinger
Journal: Annals of Oncology (2024)
175P Tislelizumab plus hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT): A prospective, signal-arm, phase II clinical study
Authors: H. Zhang, Y. Fu, W. Lu, P. Wang, H. Zhou, J. Zhai, C. Shi, W. Xiong
Journal: Annals of Oncology (2024)
129P Clinical and molecular landscape of deficient mismatch repair (dMMR) colon cancer (CC) patients: Data from a large consecutive single-center cohort
Authors: M. Bartolini, M. Airoldi, L. Giordano, V. Daprà, R. Fazio, J. Canzian, M.G. Prete, G. Mondello, M.C. Tronconi, M. Sacchi, C. Foppa, A. Destro, A. Dal Buono, T. Comito, G. D'Agostino, P. Spaggiari, M. Scorsetti, A. Spinelli, A. Santoro, A. Puccini
Journal: Annals of Oncology (2024)
150P Assessing the inflammatory profile and microbiome dynamics in colorectal cancer patients pre- and post-chemotherapy
Authors: H. Williams, E. Ruiz, E. Fernandez-Figueroa, J. Melchor-Ruan, A. Hernandez-Guerrero, J. Falcon-Martinez, J. Argueta-Donohué
Journal: Annals of Oncology (2024)
134P Rate and clinical implications of uncommon KRAS mutations in colorectal cancer
Authors: D. Ciardiello, A. Rappa, K. Venetis, L. Gervaso, G. Pellizzari, R. Adorisio, L. Bottiglieri, N. Fusco, N. Fazio, M.G. Zampino, E. Guerini Rocco
Journal: Annals of Oncology (2024)
158TiP Exploiting circulating tumor DNA (ctDNA) to intensify the adjuvant (adj) or post-adj treatment of stage III and high-risk stage II resected colon cancer patients (pts): The ERASE-CRC project by GONO
Authors: V. Conca, G. Vetere, R. Moretto, S. Lonardi, C. Antoniotti, M.M. Germani, F. Pietrantonio, A. Bittoni, M. Carullo, L. Salvatore, A. Boccaccino, M. Ronzoni, G. Ricagno, I. Toma, S. Cupini, T.P. Latiano, G. Arcangeli, G. Masi, M. Fassan, C. Cremolini
Journal: Annals of Oncology (2024)
161TiP A phase II study of mFOLFOXIRI after metastasectomy in patients with oligometastatic colorectal cancer (FANTASTIC study)
Authors: M. Ikeda, K. Kataoka, T. Yamada, K. Yamazaki, K. Mori, N. Matsuhashi, M. Shiozawa, M. Gotoh, T. Iwai, K. Ito, M. Yasui, Y. Takii, T. Suto, Y. Takamizawa, N. Takase, S. Sharma, J. Ensor, A. Jurdi, M.C. Liu, Y. Kanemitsu
Journal: Annals of Oncology (2024)
122P Immune phenotypes and histological growth patterns in resected lung metastasis of colorectal cancer patients to assess prognosis
Authors: B. Martin Cullell, A.C. Virgili Manrique, A. Piedra, C. Fumagalli, F.J. Pelegrín Mateo, P. Cerda Serda, O. Mirallas, E. Martínez, J.C. Trujillo, J. Belda-Sanchis, J. Szafranska, D. Paez
Journal: Annals of Oncology (2024)
196P Epidemiological characteristics and prognosis among patients with fibrolamellar hepatocellular carcinoma: A retrospective cohort in Mexican population
Authors: J. Cervantes Bojalil, M.D.C. Diaz Romero, V. Salais Michaus, A.W. Saenz Mamani, S. Zilli Hernández, S.M. Miyagui Adame, E. Ruiz, M. Herrera, G. Calderillo Ruiz, J. Melchor-Ruan
Journal: Annals of Oncology (2024)
174P A single-arm open-label pilot study of combination therapy of TACE in combination with ablation and durvalumab in unresectable hepatocellular carcinoma patients (TAD study)
Authors: B. Tang, J. Yuan, Z. Lu, X. Yin, R. Chen, M. Tang, Y. Gan, L. Zhang, L. Huang, Z. Ren
Journal: Annals of Oncology (2024)
181P Circulating tumor DNA (ctDNA) testing for recurrence and treatment response monitoring in hepatocellular carcinoma (HCC)
Authors: M. Abdelrahim, A. Mejia, A. Esmail, M. Ouf, J.W. Franses, I. Bhan, K. Sudha, C. Brdiges, T. Tin, C. Brewer, V. Aushev, C.C. Palsuledesai, A. Jurdi, M.C. Liu, R.M. Ghobrial, A.R. He
Journal: Annals of Oncology (2024)
157TiP A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD): The CORRECT-MRD I study
Authors: G. Srinivasan, A. Hubert, O. Purim, V. Semenisty, N. Lo, Y. Tsukada, G. Mondello, A. Cubillo, S. Subramaniam, M.R. Palomares, R.F.L. Baehner, F. De Jong, D.J. Kerr, T. Yoshino
Journal: Annals of Oncology (2024)
125P Circulating tumour DNA (ctDNA) as a prognostic biomarker in patients (pts) with refractory metastatic colorectal cancer (mCRC) receiving TAS102 with or without bevacizumab
Authors: N. Saoudi Gonzalez, V. Navarro Garces, F. Salvà Ballabrera, F.J. Ros Montana, I. Baraibar Argota, M. Rodriguez Castells, C. Vaghi, A. Garcia Rodriguez, A. Alcaraz, R. Comas, R. Dienstmann, J. Tabernero, A. Vivancos, M.E. Elez Fernandez
Journal: Annals of Oncology (2024)
146P Prognostic value of SMAD7 single nucleotide polymorphisms in colorectal cancer: A retrospective analysis
Authors: M. Peixoto, C. Oliveira, J.M. Rocha, C. Honrado Martins, M. Viana-Pereira, M.M. Pereira, D.D. Lopes, M.J. Pereira Amorim, A.D. Marques, D.S. Freitas, J. Cunha, F.M. Ferreira Pereira, R.M. Reis, E.M. Oliveira Couto
Journal: Annals of Oncology (2024)
123P The gut microbiome: A potential modulator of patient prognosis in colorectal cancer
Authors: S. Temraz, F. Nassar, R. Altartir, M. Mezher, F. Naja, P. Bertrand, A. Ghantous, V. Cahais, C. Cuenin, A.I. Shamseddine, Y. Zheng, L. Hou, H. Chatila, R. Nasr
Journal: Annals of Oncology (2024)
A geometric approach to robust medical image segmentation
Authors: Ainkaran Santhirasekaram, Mathias Winkler, Andrea Rockall, Ben Glocker
Journal: Medical Image Analysis (2024)

Robustness of deep learning segmentation models is crucial for their safe incorporation into clinical practice. However, these models can falter when faced with distributional changes. This challenge is evident in magnetic resonance imaging (MRI) scans due to the diverse acquisition protocols across various domains, leading to differences in image characteristics such as textural appearances. We posit that the restricted anatomical differences between subjects could be harnessed to refine the latent space into a set of shape components. The learned set then aims to encompass the relevant anatomical shape variation found within the patient population. We explore this by utilising multiple MRI sequences to learn texture invariant and shape equivariant features which are used to construct a shape dictionary using vector quantisation. We investigate shape equivariance to a number of different types of groups. We hypothesise and prove that the greater the group order, i.e., the denser the constraint, the better becomes the model robustness. We achieve shape equivariance either with a contrastive based approach or by imposing equivariant constraints on the convolutional kernels. The resulting shape equivariant dictionary is then sampled to compose the segmentation output. Our method achieves state-of-the-art performance for the task of single domain generalisation for prostate and cardiac MRI segmentation. Code is available at https://github.com/AinkaranSanthi/A_Geometric_Perspective_For_Robust_Segmentation.
166P Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Authors: S.L. Chan, T. Decaens, M. Kudo, J.P. Erinjeri, R. Lencioni, M. Bouattour, V.V. Breder, J. Heo, V. Mazzaferro, J-W. Park, A. Molina Alavez, K.M. Kee, A. Xu, Y. Inaba, F. Dayyani, M. Żotkiewicz, C.L. McCoy, M. Makowsky, B. Sangro
Journal: Annals of Oncology (2024)
162TiP Phase II study of consolidation treatment with holmium-166 (166Ho) TARE followed by maintenance systemic therapy (MT) in unresectable liver-limited (ULL) colorectal cancer (CRC) patients (pts) after standard first-line induction therapy: The HAITI trial
Authors: B. Borelli, I. Bargellini, M. Carullo, G. Boni, F. Pietrantonio, C. Boccaccio, L. Antonuzzo, V. Conca, S. Tamberi, A. Taravella, S. De Marco, K. Rihawi, F. Vannini, E. Bozzi, E. Dell'Aquila, A. Sartore Bianchi, L. Delliponti, C. Cremolini, L. Crocetti, G. Masi
Journal: Annals of Oncology (2024)
176P Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma
Authors: H.J. Chon, J. Heo, M.E. Reig Monzon, T. Macarulla Mercade, V. Moreno Garcia, B. Haugk, T. Ness, S. Bhoi, M. Jensen, K. Tunblad, H. Wallberg, P. Baumann, F.G. Öberg
Journal: Annals of Oncology (2024)
169P Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
Authors: L. Rimassa, F. Dayyani, R.K. Kelley, B. Sangro, S.L. Chan, C.L. McCoy, M.J. Paskow, M. Makowsky, C. Gupta, D. Ran, A. Negro, G.K. Abou-Alfa
Journal: Annals of Oncology (2024)
211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study
Authors: S. Singh, D. Halperin, S. Myrehaug, K. Herrmann, M.E. Pavel, P.L. Kunz, B. Chasen, J. Capdevila, S. Tafuto, D-Y. Oh, C. Yoo, S. Falk, T.R. Halfdanarson, I. Folitar, Y. Zhang, W.W. de Herder, D. Ferone
Journal: Annals of Oncology (2024)
167P Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Authors: M.E. Reig Monzon, V.C. Tam, B. Sangro, I. Archambeaud, R.K. Kelley, S.L. Chan, M. Kudo, G. Masi, M.J. Paskow, M. Makowsky, C. Gupta, D. Ran, A. Negro, G.K. Abou-Alfa
Journal: Annals of Oncology (2024)
121P Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
Authors: C. Vaghi, F.J. Ros Montana, M. Mambrilla, V. Navarro Garces, R. Comas, F. Salvà Ballabrera, I. Baraibar Argota, N. Saoudi Gonzalez, M. Rodriguez Castells, A. Garcia Rodriguez, A. Alcaraz, J. Tabernero, M.E. Elez Fernandez
Journal: Annals of Oncology (2024)
191P Evaluating sorafenib as second-line treatment for advanced hepatocellular carcinoma: SORA-2, an European retrospective multicenter study
Authors: C. Möhring, M. Berger, F. Sadeghlar, M-L. Berres, I-P. Radu, C. Roderburg, A. Vogel, F. Sinner, A. Pirozzi, A. Weinmann, U. Ehmer, N. Ben Khaled, T.J. Ettrich, M. Pinter, I. Schmidt-Wolf, M. Schmid, C.P. Strassburg, M.A. Gonzalez Carmona
Journal: Annals of Oncology (2024)